Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mevrometostat by Pfizer for Prostate Cancer: Likelihood of Approval
Mevrometostat is under clinical development by Pfizer and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II...
Mevrometostat by Pfizer for Small-Cell Lung Cancer: Likelihood of Approval
Mevrometostat is under clinical development by Pfizer and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Pfizer's Mevrometostat?
Mevrometostat is a small molecule commercialized by Pfizer, with a leading Phase II program in Follicular Lymphoma. According to Globaldata,...
Mevrometostat by Pfizer for Follicular Lymphoma: Likelihood of Approval
Mevrometostat is under clinical development by Pfizer and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...
Mevrometostat by Pfizer for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Mevrometostat is under clinical development by Pfizer and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...